Katlama Christine

Médecine générale

Hôpital Pitie Salpetriere
Paris, France

439 Activités

195 Followers

Scientifique

Digital

Production scientifique

Activités par an

Expertise

Sujets de recherche

Infections à VIH Hépatite Hépatite C Virémie Syndrome d'immunodéficience acquise Co-infection Hépatite B Hépatite C chronique Maladies transmissibles

Collaborateurs

Heliot-Marcelin Anne-Genevieve

Hôpital Pitie Salpetriere, Paris, France

Valantin Marc-Antoine

Hôpital Pitie Salpetriere, Paris, France

Calvez Vincent

Hôpital Pitie Salpetriere, Paris, France

Tubiana Roland

Hôpital Pitie Salpetriere, Paris, France

Industries

MSD

43 collaboration(s)

Dernière en 2023

ViiV Healthcare

36 collaboration(s)

Dernière en 2023

Gilead

4 collaboration(s)

Dernière en 2023

ATHENEUM PARTNERS GMBH

4 collaboration(s)

Dernière en 2023

Dernières activités

Easy-Tests Study: Acceptability of a PrEP Program Among MSM and TG Visiting a Geolocated Community Application or a Community Physical Place of Sociability and Having Accepted a Targeted Screening for HIV, Hepatitis B, C and STIs.

Essai Clinique (Centre de santé sexuelle Le 190) 26 février 2024

Dataids_PEC: Dataids Prospective Observational Cohort on Quality of Care of French HIV Infected Patients

Essai Clinique (DatAids) 26 février 2024

Dat'Aids Prevention: HIV Prevention in France : "Dat'AIDS Prevention"

Essai Clinique (DatAids) 26 février 2024

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).

Microbiology spectrum 01 février 2024

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients: A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)

Essai Clinique (ViiV Healthcare) 29 janvier 2024

Dolutegravir/rilpivirine (DTG/RPV) therapy as a maintenance treatment in PLWH with past virological failures and resistance-associated mutations to NNRTIs and INSTIs